Skip to content

Neuronetics STIM Net Change in Cash

Net Change in Cash at other companies

LifeStance Health Group logo
LifeStance Health GroupLFST
-$53.85M-166%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$70.51M+2,340%
CVRx, Inc. logo
CVRx, Inc.CVRX
-$3.41M-4.3%
Stereotaxis logo
StereotaxisSTXS
$1.2M+168%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-$6.18M-146%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
-$446.5M-1,048%

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-56.2%
Enterprise value$162.64M-42.0%
P/S0.6×-1.3×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Return on equity-152.4%-1.4pp
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Neuronetics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's net change in cash?
Neuronetics (STIM) reported net change in cash of -$15.17M in Q1 2026.
How has Neuronetics's net change in cash changed year-over-year?
Neuronetics's net change in cash decreased by 959.5% year-over-year, from $1.77M to -$15.17M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.